Globalworld globe
United Kingdom
North America
Europe
  • facebook
  • linkedin
Medical Developments International
  • Home
  • Products
    • Asthma & COPD
    • Penthrox
    • Medical Devices
    • Veterinary
  • About
    • Distributor Information
    • Careers
    • Associations
  • Investors/Media
    • Financial Reports
    • Board of Directors/Management
    • Corporate Governance
    • Media Centre
    • Diversity Policy
    • Share Trading Policy
  • Healthcare Professionals
  • Contact

News

Penthrox approved in Italy, The Czech Republic and Spain

Jul 16, 2018Mark EdwardsNews

16 July 2018

ASX Announcement

Penthrox approved in Italy, The Czech Republic and Spain.

Medical Developments International Limited (ASX: MVP) is delighted to announce that Penthrox has been approved for sale in Italy,?the Czech Republic and Spain.

MVP CEO, Mr. John Sharman said, ?We are delighted to have received the approval for these countries and we expect sales to commence in these markets during FY19. This leaves just two further European approvals pending ? Luxembourg and Lithuania, with these approvals considered imminent.”

For the actual ASX announcements, please refer to the attached links – Penthrox approved in Italy and the Czech Republic and Penthrox approved in Spain

Contact Us

for information on our range of products

Find a distributor

in our global network

Investors

invest in a company with
innovative foresight

News

  • Appointment of Non-Executive Director – Mary Sontrop

    5 March 2021 ASX ANNOUNCE...

  • FY21 Half Year Report and Accounts

    26 February 2021 ASX ANNO...

  • MVP Completes $25m Placement

    14 December 2020 ASX ANNO...

Healthcare Professional Registration

Login to access healthcare professional resources



Remember Me


Forgot password? | Register

Medical Developments International

Address:
4 Caribbean Drive, Scoresby,
Victoria, 3179
Australia
Phone: +61 3 9547 1888
Email: mdi@medicaldev.com
ABN: 14 106 340 667
For Medical Enquiries:

Phone: 1800 PENTHROX (1800 736 847)
Email: medinf@medicaldev.com

Email Newsletter

Sign up to our newsletter to receive MDI corporate, investor  & media news.